Genmab — Februar 2021
-
En anden krølle er "good faith" princippet, som også medfører en stærk begrænsning af forhandlingstaktikken og medfører, at man ikke kan forhandle efter "revolver-princippet" men bl.a. skal være fair og fornuftig over for den indgående (patent)aftale
-
I agree. I may have an old suitable shoe to consume if the arbitration should fail.
-
Der er uendeligt mange fordele ved voldgift, det går hurtigere, intet kommer ud til offentligheden, parterne kan selv vælge dommerne, jurister, kommercielle personer, fagfolk med særligt kendskab til specielle brancher. Federal Arbittration Act. er forpligtet til at afvise søgsmål og henvise sagsøgerens. til voldgiftafgørelsen
i overensstemmelse med aftalen. -
God morgen.
-
Asien: Generel fremgang men Tokyo halter efter: https://www.proinvestor.com/investornyt/671940/asien-generel-fremgang-men-tokyo-halter-efter
-
Onsdagens aviser med Demant, Danske Bank og TDC: https://www.proinvestor.com/investornyt/671939/onsdagens-aviser-med-demant-danske-bank-og-tdc
-
Aktier/tendens: Vild regnskabsdag med A.P. Møller-Mærsk og mange andrehttps://www.proinvestor.com/investornyt/671958/aktier-tendens-vild-regnskabsdag-med-ap-moller-maersk-og-mange-andre
-
if anyone has access to scrip.pharmaintelligence.informa ; you can tell us if there is anything useful in this article
https://scrip.pharmaintelligence.informa.com/SC143792/Genmab-Commercial-Expansion-Opens-The-Door-To-New-Types-Of-Deals -
Looks interesting...
-
Several drugs developed by Genmab A/S are already on the market, but the company is planning to participate in its first commercial launch in 2021. Genmab is preparing for the US launch of the antibody-drug conjugate tisotumab vedotin for metastatic cervical cancer in the second half of the year in partnership with Seagen Inc. , if it is approved by the US Food and Drug Administration as expected.
The companies plan to file tisotumab vedotin for accelerated approval for metastatic cervical canc
-
cancer based on positive Phase II data. (Also see "Genmab And Seattle Genetics Progress Cervical Cancer ADC" - Scrip, 30 Jun, 2020.)
It is a transitional year for Genmab as it begins to build out a commercial footprint for the first time. The Danish biotech has developed several drugs that have reached the market, but those drugs have been launched by the company's partners. They include Johnson & Johnson's Darzalex (daratumumab), Novartis AGs' Kesimpta (ofatumumab) and Horizon Therapeutics plc
-
Tepezza (teprotumumab) – and Genmab receives sales royalties on all of them.
"This is probably one of our most exciting years ever for the company," CEO Jan van de Winkel said in a recent interview. "To become an end-to-end integrated biotech, a powerhouse, directly delivering new molecules to patients with the Genmab name on the vial is a big thrill for us."
The company is taking a cautious, stepwise approach to building out a commercial organization, focusing on the US and Japan. The team wi
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind